Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Raw Materials (2020 - 2021)

UroGen Pharma's Raw Materials history spans 2 years, with the latest figure at $2.4 million for Q1 2021.

  • For Q1 2021, Raw Materials changed N/A year-over-year to $2.4 million; the TTM value through Mar 2021 reached $2.4 million, changed N/A, while the annual FY2020 figure was $1.1 million, N/A changed from the prior year.
  • Raw Materials reached $2.4 million in Q1 2021 per URGN's latest filing, up from $1.1 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $2.4 million in Q1 2021 to a low of $893000.0 in Q2 2020.